McKesson ideaShare 2018 vendors donate items to Nevada Childhood Cancer Foundation
More than 170 exhibitors of McKesson ideaShare 2018 closed out the annual conference held this week in Las Vegas with a donation of 1000s of personal hygiene items, including soap, shampoo and toothpaste to Nevada Childhood Cancer Foundation on behalf of families of children diagnosed with cancer.
Established in 1993, NCCF is a local non-profit organization providing over 45 programs and services at no cost to pediatric and adult patients and their families living in Southern Nevada. The NCCF’s goal is to improve the quality of life for critically ill children, their families and adults touched by cancer in the community. When a child is diagnosed with cancer or other life-threatening illness they look to NCCF for support, hope, and courage.
Amneal looks to streamline its new operation
Fresh off closing its acquisition of Impax Labs, Bridgewater, N.J.-based Amneal Pharmaceuticals will be making streamlining efforts that will reduce its workforce by roughly 550 jobs. The company is set to close its Hayward, Calif.-based facilities and operations — formerly the site of Impax’s headquarters.
The company said the facilities would be phased out over the course of 15 months, with plans to transfer the products manufactured there to lower-cost U.S. and India facilities. Amneal president and CEO Rob Stewart noted that the move is aimed at creating $1.1 billion of adjusted EBITDA by the end of 2020, with the company expecting “a significant favorable impact beginning in 2019” from the closing.
“I recognize that these types of announcements are difficult for our colleagues. We have announced and are committed to implementing a comprehensive transition plan,” Stewart said. “We will also work toward an orderly wind-down of the Hayward facilities to ensure these actions cause minimal disruptions to customers and patients. I have asked teams across our company for their full support of our colleagues in Hayward as we work together through this difficult transition.”
Amneal said it would provide further information about the financial impact and pre-tax restructuring charges in a future filing.
Mylan enters Humira biosimilar commercialization partnership
Mylan is working with Fujifilm Kyowa Kirin Biologics to commercialize a Humira biosimilar through a recently announced partnership. The Pittsburgh-based company said it would use its regulatory platform to submit Fujifilm Kyowa Kirin Biologics’ Humira biosimilar for approval and commercialization in Europe.
Humira, indicated to treat multiple chronic inflammatory conditions, had European sales of roughly $4.1 billion for the 12 months ended Dec. 31, 2017, according to IQVIA data.
“Expanding access to biologics through the introduction of biosimilars around the world is a key area of focus for Mylan,” CEO Heather Bresch said. “Our partnership with Fujifilm Kyowa Kirin Biologics for an adalimumab biosimilar in Europe is an exciting advancement for Mylan and for patients who are living with chronic autoimmune conditions and need access to a high-quality, more affordable treatment option.”
Mylan said it expects to receive a decision from the European Medicines Agency in the second half of 2018 for the Humira biosimilar. The agreement will see Mylan paying an upfront fee to Fujifilm Kiowa Kirin Biologics, with eligibility for a subsequent commercialization milestone payment and sales royalties.
“Expanding access to biologics through the introduction of biosimilars around the world is a key area of focus for Mylan,” Rajiv Malik, Mylan president, said. “Our partnership with Fujifilm Kyowa Kirin Biologics for an adalimumab biosimilar in Europe is an exciting advancement for Mylan and for patients who are living with chronic autoimmune conditions and need access to a high-quality, more affordable treatment option.”